The pathological characteristics and outcomes of 40 surgically treated stage M1b non-small cell lung cancer patients
Pan, Y.; Wang, Y.L.; Wang, Y.G.; Wang, D.L.
Zhonghua Zhong Liu Za Zhi 41(1): 63-67
2019
ISSN/ISBN: 0253-3766 PMID: 30678419 Document Number: 698469
目的: 探讨行手术干预的M1b期非小细胞肺癌(NSCLC)患者的临床病理特征和预后影响因素。 方法: 回顾性分析1999年1月至2012年12月中国医学科学院肿瘤医院胸外科收治的40例M1b期NSCLC患者的临床资料,其中男24例,女16例。采用Kaplan-Meier法、log rank检验和Cox比例风险回归模型分析患者的预后及其影响因素。 结果: 40例患者的1、3、5年生存率分别为70.0%、40.0%和22.5%,中位生存时间为31.5个月。行原发肿瘤切除术和转移灶局部治疗的患者23例,其中位生存时间为41.5个月,高于仅行原发肿瘤切除术者(13例,中位生存时间为15.5个月)和开胸探查活检术者(4例,中位生存时间为14.5个月),差异均有统计学意义(均P<0.05)。多因素分析显示,有无胸腔积液、有无脑寡转移灶、是否术后接受化疗和靶向治疗均为影响患者预后的独立因素(均P<0.05)。 结论: 行手术治疗的M1b期NSCLC患者的总生存时间较长,极个别患者甚至可获得长期生存,筛选合适的患者接受原发灶切除和转移灶局部治疗可能给患者带来极大益处。.
Document emailed within 1 workday
Related Documents
Wiatr, E.; Bestry, I.; Zych, J.; Grymiński, J. 1993: Stage and regression time of radiological changes in patients treated for small cell lung cancer Pneumonologia i Alergologia Polska 61(1-2): 46-51Neill, H.B.; Miller, A.A.; Clamon, G.H.; Perry, M.C.; Crawford, J.; Green, M.R. 1997: A phase Ii study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12
Rybojad, P.ł; Dłuski, D.; Rybojad, B.; Kędra, M.; Sawicki, M.; Skoczylas, P.; Tabarkiewicz, J. 2013: Urban vs. rural patients. Differences in stage and overall survival among patients treated surgically for lung cancer Annals of Agricultural and Environmental Medicine: Aaem 20(1): 101-105
2016: (S040) Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Predicted Worse Outcomes in Patients With Limited-Stage Small-Cell Lung Cancer Oncology 30 Suppl
Huang, Z.Y.; Li, H.Z.; Xu, P.Q. 1988: Pathological findings and prognosis in 202 patients with small cell lung cancer Zhonghua Zhong Liu Za Zhi 10(1): 38-41
Niemiec, J.; Kołodziejski, L.; Dyczek, S.; Gasińska, A. 2004: Prognostic significance of epidermal growth factor receptor in surgically treated squamous cell lung cancer patients Folia Histochemica et Cytobiologica 42(2): 111-118
Sun, C-Jin.; Yang, Z-Gang.; Zhou, X-Ping.; Zhou, Q-Hua.; Sun, J-Tao.; Zhang, S-Fu.; Li, J.; Yu, J-Ming.; Zhang, L. 2007: Non-small cell lung cancer evaluated by first pass dynamic contrast-enhanced 16-slice spiral CT: correlation of tumor vascularity with pathological characteristics Zhonghua Zhong Liu Za Zhi 29(6): 429-433
Ziske, C.; Gorschlüter, M.; Mey, U.; Offergeld, R.; Glasmacher, A.; Schmidt-Wolf, I.G.H. 2002: Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer Anticancer Research 22(6b): 3723-3726
Mørkve, O.; Halvorsen, O.J.; Skjaerven, R.; Stangeland, L.; Gulsvik, A.; Laerum, O.D. 1993: Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas Anticancer Research 13(3): 571-578
Uchikov, A.; Murdzhev, K.; Batashki, I.; Prisadov, G.; Uchikova, E. 2007: Remote results in operated patients with non-small cell lung cancer in IIi clinical stage Khirurgiia 5: 41-42
Cohen, M.H. 1983: Is thoracic radiation therapy necessary for patients with limited-stage small cell lung cancer? no Cancer Treatment Reports 67(3): 217-221
Alsan Cetin, I.; Akgun, Z.; Atasoy, B.M.; Fulden Yumuk, P.; Abacioglu, U. 2013: Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients? Journal of BUON: Official Journal of the Balkan Union of Oncology 18(2): 453-458
Ishida, T.; Kaneko, S.; Akazawa, K.; Tateishi, M.; Sugio, K.; Sugimachi, K. 1993: Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients Cancer Research 53(20): 5000-5003
Dell'amore, A.; Monteverde, M.; Caroli, G.; Sanna, S.; Stella, F.; Bini, A. 2013: Surgical results and survival of older patients with unsuspected N₂ (stage IIIA) non-small cell lung cancer Il Giornale di Chirurgia 34(3): 53-58
Sahin, C.; Omar, M.; Tunca, H.; Kalemci, S.; Ozseker, B.; Akbaba, G.; Tanriverdi, O. 2015: Weight loss at the time of diagnosis is not associated with prognosis in patients with advanced-stage non-small cell lung cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 20(6): 1576-1584
Fram, R.; Skarin, A.; Balikian, J.; Amato, D.; Leslie, N.; Malcolm, A.; Frei, E. 1985: Combination chemotherapy followed by radiation therapy in patients with regional stage IIi unresectable non-small cell lung cancer Cancer Treatment Reports 69(6): 587-590
Evans, W.K. 1997: Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module Seminars in Oncology 24(2 Suppl 7: S7
Goldberg, M. 2000: Multimodality therapy in surgically resectable early non-small cell lung cancer In Vivo 14(1): 51-60
Graziano, S.L.; Tatum, A.H.; Newman, N.B.; Oler, A.; Kohman, L.J.; Veit, L.J.; Gamble, G.P.; Coleman, M.J.; Barmada, S.; O'Lear, S. 1994: The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage i and Ii non-small cell lung cancer Cancer Research 54(11): 2908-2913
Mańdziuk, S.ła.; Dudzisz-Sledź, M.; Korszeń-Pilecka, I.; Milanowski, J.; Wojcierowski, J.; Korobowicz, E. 2003: Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 58(1): 154-157